Type of information: Fundraising
Company: Vectivbio (Switzerland)
Investors: Versant Ventures (USA) OrbiMed (USA) Novo Holdings (Denmark) BPI France (France) Tekla Healthcare Investors (USA) Inserm Transfer Initiative (France) Cowen Healthcare Investments (USA) Surveyor Capital (USA) Eventide Asset Management (USA)
Amount: $110 Million
Funding type: financing round
Planned used: Proceeds from the financing will be used to support the Phase III program of VectivBio’s lead investigational product, apraglutide, to treat short bowel syndrome (SBS), early commercialization activities and further development of the pipeline through business development initiatives. Phase II studies of apraglutide demonstrated the potential for once-weekly dosing.
Therapeutic area: Inflammatory diseases - Gastrointestinal diseases - Transplantation